Olmesan 20 Tablet
by Beximco Pharmaceuticals Ltd.
৳10.00
Aristopharma Ltd.
PRESULOCK 20 mg Tablet by Aristo pharmaceutical Ltd is available in our online pharmacy. Place your order in osudpotro and get online medicine home delivery.
Olmesartan medoxomil is suitable for the treatment of hypertension. It can be used alone or in combination with other antihypertensive drugs.
Angiotensin enzymes (Aces) formed from angiotensinisin are potent vasoconstructors, primary vascular hormones of diotensin Leninan and physiopathological components of hypertension. It also stimulates the secretion of aldosterone by the adrenal cortex. The almeltin blocks the effects of vasoconstructive and altosthenical secretion of Angiotensiney, selectively blocking the angiotensini junction to the AT A 1 receptor in many tissues (eg, vascular smooth muscle, adrenal kidney). Invobinding studies indicates that the ormesartan is reversible and competitive inhibitors of a receiver. Almesartan does not inhibit ACE (Kinasasei, Angiotensini Angiotensini and Breakpe Bradykinin).
Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.
Co-administration with drugs: When olmesartan is co-administered, no significant drug interactions have been reported. and food and others: food does not affect the bioavailability of Olmesartan.
Olmesartan is contraindicated in patients who are allergic to any component of this product.
Common: The most common side effects include back pain, bronchitis, elevated creatine phosphokinase, diarrhea, headache, haematuria, hyperglycaemia, hypertriglyceridaemia, flu-like symptoms, pharyngitis, rhinitis, and sinusitis.
Rare: chest pain, peripheral edema, arthritis.
Pregnancy: When pregnancy is detected, please stop this product as soon as possible. When drugs are used in the second and third trimesters of pregnancy, drugs that directly act on the renin-angiotensin system can cause harm or even death to the developing fetus.
Nursing mothers: It is not clear whether Olmesartan is secreted in human milk, but low concentrations of Olmesartan are secreted in the milk of lactating rats. Due to the possibility of adverse reactions in breastfeeding infants, the importance of the drug to the mother should be considered and the decision to stop breastfeeding or medication should be stopped.
Because the renin angiotensin aldosterone system is inhibited, changes in renal function can be expected in susceptible individuals receiving olmesartan medoxomil treatment. For patients whose renal function may depend on the activity of the renin-angiotensin aldosterone system (for example, patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists is associated with oliguria and/ Or progressive azotemia, and (rarely) with acute renal failure. Failure and/or death. Similar results can be expected in patients treated with olmesartan medoxomil.
Angiotensin-ll receptor blocker
Store in cool & dry place below 30ºC, protect from light & moisture. Keep out of the reach of children.
by Opsonin Pharma Limited
৳10.00